JP2007521835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521835A5 JP2007521835A5 JP2006553250A JP2006553250A JP2007521835A5 JP 2007521835 A5 JP2007521835 A5 JP 2007521835A5 JP 2006553250 A JP2006553250 A JP 2006553250A JP 2006553250 A JP2006553250 A JP 2006553250A JP 2007521835 A5 JP2007521835 A5 JP 2007521835A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- treating
- dietary supplement
- suspected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 6
- 235000015872 dietary supplement Nutrition 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 230000001851 biosynthetic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 235000020956 nicotinamide riboside Nutrition 0.000 claims 1
- 239000011618 nicotinamide riboside Substances 0.000 claims 1
- 108010021066 nicotinamide riboside kinase Proteins 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54334704P | 2004-02-10 | 2004-02-10 | |
| PCT/US2005/004337 WO2005077091A2 (en) | 2004-02-10 | 2005-02-09 | Nicotinamide riboside kinase compositions and methods for using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007521835A JP2007521835A (ja) | 2007-08-09 |
| JP2007521835A5 true JP2007521835A5 (https=) | 2008-05-22 |
Family
ID=34860407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553250A Pending JP2007521835A (ja) | 2004-02-10 | 2005-02-09 | ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8197807B2 (https=) |
| EP (1) | EP1723227A4 (https=) |
| JP (1) | JP2007521835A (https=) |
| AU (1) | AU2005211773B2 (https=) |
| CA (1) | CA2555675A1 (https=) |
| WO (1) | WO2005077091A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114626B2 (en) * | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| US20050227327A1 (en) * | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| EP2805719A1 (en) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US20100047177A1 (en) * | 2007-01-26 | 2010-02-25 | Washington University | Methods and compositions for treating neuropathies |
| CA2928656C (en) | 2013-10-30 | 2020-07-28 | ChromaDex Inc. | Nicotinamide riboside compositions for topical use in treating skin conditions |
| CA2951287A1 (en) | 2014-06-06 | 2015-12-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
| CN106715454B (zh) | 2014-07-24 | 2020-06-16 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
| KR102629310B1 (ko) | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | 니코틴아미드 리보사이드의 결정 형태 |
| CN107531738B (zh) * | 2015-03-16 | 2021-02-19 | 可劳迈戴斯有限公司 | 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途 |
| WO2016178945A1 (en) * | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| KR102114892B1 (ko) | 2016-01-11 | 2020-05-26 | 더 프록터 앤드 갬블 캄파니 | 피부 상태의 치료 방법 및 그를 위한 조성물 |
| CA3017254C (en) | 2016-03-16 | 2023-08-22 | ChromaDex Inc. | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof |
| US10183036B2 (en) | 2016-04-20 | 2019-01-22 | ChromaDex Inc. | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors |
| CA3045876A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| MX2019006278A (es) | 2016-11-29 | 2019-08-21 | Univ Iowa Res Found | Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| EP3642214A2 (en) | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| WO2018237218A1 (en) | 2017-06-23 | 2018-12-27 | The Procter & Gamble Company | COMPOSITION AND METHOD FOR ENHANCING SKIN APPEARANCE |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| KR20210011964A (ko) | 2018-07-03 | 2021-02-02 | 더 프록터 앤드 갬블 캄파니 | 피부 병태를 치료하는 방법 |
| CN112654264A (zh) | 2018-09-27 | 2021-04-13 | 雀巢产品有限公司 | 使用至少一种甘氨酸或其衍生物、至少一种n-乙酰半胱氨酸或其衍生物和至少一种烟酰胺核糖核苷或nad+前体的组合物和方法 |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| WO2020172338A1 (en) * | 2019-02-19 | 2020-08-27 | Whitehead Institute For Biomedical Research | Methods and agents for modulating mitochondrial nad levels |
| US20220125814A1 (en) * | 2019-03-21 | 2022-04-28 | Fred Hutchinson Cancer Research Center | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor |
| US20220168271A1 (en) * | 2019-03-29 | 2022-06-02 | Societe Des Produits Nestle S.A. | Compositions and methods for increasing t cell function |
| US20200397807A1 (en) | 2019-06-18 | 2020-12-24 | MitoPower, LLC | Nicotinyl riboside compounds and their uses |
| CN110412157A (zh) * | 2019-07-17 | 2019-11-05 | 广州金评检测研究院有限公司 | 一种烟酰胺原料中烟酸的测定方法 |
| EP3999518A2 (en) | 2019-07-19 | 2022-05-25 | Biosynth AG | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof |
| EP4125852A1 (en) | 2020-04-01 | 2023-02-08 | Société des Produits Nestlé S.A. | Compositions and methods containing n-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| CN115843238B (zh) | 2020-06-01 | 2025-06-10 | 宝洁公司 | 改善维生素b3化合物渗透到皮肤中的方法 |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| WO2022106407A1 (en) | 2020-11-18 | 2022-05-27 | Société des Produits Nestlé S.A. | Compositions and methods using a combination of oleuropein and nicotinamide riboside for cellular energy |
| CN112553178B (zh) * | 2020-12-25 | 2023-03-10 | 中山俊凯生物技术开发有限公司 | 热稳定性和活性增强的烟酰胺核糖激酶突变体及其编码基因和应用 |
| US12295960B2 (en) | 2021-10-17 | 2025-05-13 | University of South Alabama Foundation for Research and Commercialization | Cancer treatment |
| LT7046B (lt) | 2022-04-15 | 2024-02-12 | Vilniaus Universitetas | Hidrolazės ir jų panaudojimas |
| CN115896062B (zh) * | 2022-08-10 | 2024-10-01 | 福建师范大学 | 一种烟酰胺核糖苷激酶突变体及其相关产品和应用 |
| LT7066B (lt) | 2023-11-17 | 2024-06-25 | Vilimas Vladas | Didelės talpos medžio sulos atitirpinimo būdas |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| EP0452457B1 (en) | 1989-11-03 | 1997-08-20 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| PT728214E (pt) | 1993-11-09 | 2004-11-30 | Ohio Med College | Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5623054A (en) | 1994-06-23 | 1997-04-22 | The General Hospital Corporation | Crucifer AFT proteins and uses thereof |
| CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| ES2150832B1 (es) | 1996-06-12 | 2001-06-16 | Fichtel & Sachs Ag | Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion. |
| JP2001506132A (ja) | 1996-12-18 | 2001-05-15 | ターゲティッド ジェネティクス コーポレイション | Ａａｖベクターの産生における使用のためのリコンビナーゼ活性化可能ａａｖパッケージングカセット |
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| EP1228222A2 (en) * | 1999-11-04 | 2002-08-07 | Incyte Genomics, Inc. | Human transferase molecules |
| CA2399776A1 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20030175925A1 (en) * | 2001-02-27 | 2003-09-18 | Oleg Kurnasov | Nicotinamide ribonucleoside kinase |
| AU2004205785A1 (en) * | 2003-01-23 | 2004-08-05 | Eirx Therapeutics Limited | Kinases and GPCRs involved in apoptosis |
| EP2384753B1 (en) * | 2003-08-29 | 2016-01-06 | The Brigham and Women's Hospital, Inc. | Hydantoin derivatives as inhibitors of cellular necrosis |
-
2005
- 2005-02-09 EP EP05722944A patent/EP1723227A4/en not_active Withdrawn
- 2005-02-09 AU AU2005211773A patent/AU2005211773B2/en not_active Ceased
- 2005-02-09 WO PCT/US2005/004337 patent/WO2005077091A2/en not_active Ceased
- 2005-02-09 JP JP2006553250A patent/JP2007521835A/ja active Pending
- 2005-02-09 CA CA002555675A patent/CA2555675A1/en not_active Abandoned
-
2006
- 2006-04-20 US US11/912,400 patent/US8197807B2/en active Active
- 2006-10-04 US US11/542,832 patent/US20070027095A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,289 patent/US8383086B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007521835A5 (https=) | ||
| MX2009011357A (es) | Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos. | |
| Weimann et al. | ESPEN guidelines on enteral nutrition: surgery including organ transplantation | |
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| MX2009002920A (es) | Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos. | |
| WO2008082602A3 (en) | Compounds and pharmaceutical compositions for the treatment of liver disorders | |
| JP2008150375A5 (https=) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| MX2010001560A (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv. | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| MX2010001696A (es) | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo. | |
| EP4541418A3 (en) | Assays for diagnosing and evaluating treatment options for fabry disease | |
| WO2008052044A3 (en) | Use of derivatives of propofol for treating diseases associated with oxidative stress | |
| BRPI0922796A2 (pt) | Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo | |
| MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
| Manjunath et al. | Adenosine and adenosine receptors: Newer therapeutic perspective | |
| WO2008149802A1 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
| JP2009537554A5 (https=) | ||
| TW200740452A (en) | Therapeutic gastrodia extracts | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| UA99598C2 (ru) | Применение экстракта эвкалипта для лечения или профилактики расстройств, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина | |
| FR2921927B1 (fr) | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers | |
| NO20054382L (no) | Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel | |
| WO2007023154A3 (de) | EISEN(III)-KOMPLEXVERBINDtMGEN ZUR BEHANDLUNG VON EISENMANGEL-ZUSTÄNDEN BEI PATIENTEN MIT CHRONISCH-ENTZÜNDLICHER DARMERKRANKUNG | |
| ATE554775T1 (de) | Phospholipid-zusammensetzungen und ihre verwendungen |